InhaleRx Limited

Equities

IRX

AU0000179475

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 02:10:19 2024-05-24 am EDT			5-day change	1st Jan Change
0.03 ^AUD	-25.00%		-.--%	+3.45%

May. 30	InhalerX Files Investigational New Drug Application with US FDA for Drug-Device Pain Medication	MT
Mar. 28	InhaleRx Limited announced that it expects to receive AUD 0.5 million in funding from Peak Asset Management, LLC	CI

Lifespot Health Limited Announces Resignation of Heiner Emden as Director

January 31, 2019 at 05:08 pm EST

Lifespot Health Limited announced that Heiner Emden has resigned as a director of the Company. He will continue in the role of Head of software development reporting to Gregor Schommer, Managing Director Bodytel.

Latest news about InhaleRx Limited

InhalerX Files Investigational New Drug Application with US FDA for Drug-Device Pain Medication	May. 30	MT
InhaleRx Limited announced that it expects to receive AUD 0.5 million in funding from Peak Asset Management, LLC	Mar. 27	CI
InhaleRx Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
InhaleRx to Focus on Breakthrough Cancer Pain for Phase 2 Trial of Cannabinoid Analgesic	Jan. 10	MT
InhaleRx Secures Nearly AU$550,000 R&D tax Incentive Prepayment	Dec. 21	MT
InhaleRX Completes Phase One Trial for Pain Medication Device	Dec. 04	MT
InhaleRx Files Ethics Application for Panic Disorder Trial	23-10-17	MT
InhaleRx Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
InhaleRx Limited Announces Change of Registered Office Address	23-08-02	CI
InhaleRx Limited Announces Executive Changes	23-08-02	CI
InhaleRx Completes First Cohort of Phase One Clinical Trial	23-06-14	MT
Australian Shares Retreat Anew on Rate Hike, Slower-than-Expected GDP Growth	23-06-07	MT
InhaleRx Doses First Individuals for Phase One Trial of Inhalable Pain Medication	23-06-07	MT
InhaleRx Limited Auditor Raises 'Going Concern' Doubt	23-03-29	CI
InhaleRx Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-26	CI
InhaleRx Hires Contract Research Organization for Upcoming Clinical Trials	22-12-22	MT
Inhalerx Limited Announces Fda Pre-Ind Application Update	22-12-11	CI
InhaleRx Limited Announces Board and Management Changes	22-09-26	CI
InhaleRx Limited Announces the Appointment of Darryl Davies as Chief Executive Officer	22-09-26	CI
InhaleRx Raises $810,000 From Share Placement	22-09-18	MT
InhaleRx Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
InhaleRx Limited Auditor Raises 'Going Concern' Doubt	22-03-30	CI
InhaleRx Secures Licenses to Sell, Supply Controlled Substances	22-03-30	MT
Victorian Department of Health & Human Services Grants Wholesale Licenses to Inhalerx Limited to Sell and Supply Poisons or Controlled Substances	22-03-29	CI
InhaleRx Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-27	CI

Chart InhaleRx Limited

Duration

Period

More charts

Company Profile

Inhalerx Limited is an Australia-based healthcare company. The Company is focused on developing medicinal drug-device products to address unmet medical needs in the pain management and mental health sectors. The Company partners with educators in their technical and therapeutic fields, to provide inhalation therapies that deliver added value for patients, doctors, business partners, governments, and stakeholders alike. Its Medihale Inhaler is a sealed pod inhaler designed specifically for use with inhaled formulations. It utilizes heat (not burn) technology, avoiding the production of pyrolytic toxins and carcinogenic often created when combusting plant material. The sealed tamper-proof Medihale Pods provide patients with additional security. The Medihale Protective Charging Case automatically recharges the Medihale Inhaler when the inhaler is returned to its case. The Medihale Protective Charging Case even has a dedicated storage space to carry an extra Medihale c-liquid Pod.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
INHALERX LIMITED	+3.45%	3.78M
THERMO FISHER SCIENTIFIC	+7.01%	217B
DANAHER CORPORATION	+11.01%	190B
INTUITIVE SURGICAL, INC.	+19.20%	143B
BOSTON SCIENTIFIC CORPORATION	+30.79%	111B
SIEMENS HEALTHINEERS AG	+1.48%	64.59B
EDWARDS LIFESCIENCES CORPORATION	+13.95%	52.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.16%	48.45B
AGILENT TECHNOLOGIES, INC.	-6.20%	38.03B
GE HEALTHCARE TECHNOLOGIES INC.	+0.91%	35.6B

Other Advanced Medical Equipment & Technology